Are the Results from a Multiplex Proteomic Assay and a Conventional Immunoassay for NT-proBNP and GDF-15 Comparable?

Overview

Journal Clin Proteomics

Publisher Biomed Central

Date 2023 Jan 24

PMID 36694116

Authors

Emma Skau

Philippe Wagner

Jerzy Leppert

Johan Arnlov

Par Hedberg

Affiliations

Soon will be listed here.

Abstract

Background: We aimed to compare absolute plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) and growth differentiation factor 15 (GDF-15) obtained by a conventional immunoassay with the corresponding relative concentrations from a proximity extension assay (PEA) and compare the prognostic impact of the protein levels obtained from these assays.

Methods: We evaluated 437 patients with peripheral arterial disease (PAD) and a population-based cohort of 643 individuals without PAD. Correlations were calculated using Spearman's rank correlation coefficients (rho). The discriminatory accuracy of the protein levels to predict future cardiovascular events was analyzed with Cox regression and presented as time-dependent areas under the receiver-operator-characteristic curves (tdAUCs).

Results: For NT-proBNP, the two assays correlated with rho 0.93 and 0.93 in the respective cohort. The PEA values leveled off at higher values in both cohorts. The corresponding correlations for GDF-15 were 0.91 and 0.89. At 5 years follow-up, the tdAUCs in the patient cohort were similar for NT-proBNP and GDF-15 regardless of assay used (0.65-0.66). The corresponding tdAUCs in the population-based cohort were between 0.72 and 0.77.

Conclusion: Except for the highest levels of NT-proBNP, we suggest that PEA data for NT-proBNP and GDF-15 reliably reflects absolute plasma levels and contains similar prognostic information.

References

Conden E, Rosenblad A, Wagner P, Leppert J, Ekselius L, Aslund C . Is type D personality an independent risk factor for recurrent myocardial infarction or all-cause mortality in post-acute myocardial infarction patients?. Eur J Prev Cardiol. 2017; 24(5):522-533. DOI: 10.1177/2047487316687427. View

Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen S, Ekman D . Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014; 9(4):e95192. PMC: 3995906. DOI: 10.1371/journal.pone.0095192. View

Shen Q, Polom K, Williams C, Marques Souza de Oliveira F, Guergova-Kuras M, Lisacek F . A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer. EBioMedicine. 2019; 44:322-333. PMC: 6606959. DOI: 10.1016/j.ebiom.2019.05.044. View

Nordin G . Accuracy of HbA1c as Monitored by External Quality Assessment and Compared With Patient Mean Values. J Diabetes Sci Technol. 2018; 12(4):771-779. PMC: 6134316. DOI: 10.1177/1932296818785622. View

Wollert K, Kempf T, Giannitsis E, Bertsch T, Braun S, Maier H . An Automated Assay for Growth Differentiation Factor 15. J Appl Lab Med. 2020; 1(5):510-521. DOI: 10.1373/jalm.2016.022376. View

Akamatsu S, Tsukazaki H, Inoue K, Nishio Y . Advanced prostate cancer with extremely low prostate-specific antigen value at diagnosis: an example of high dose hook effect. Int J Urol. 2006; 13(7):1025-7. DOI: 10.1111/j.1442-2042.2006.01467.x. View

Aslam B, Basit M, Nisar M, Khurshid M, Rasool M . Proteomics: Technologies and Their Applications. J Chromatogr Sci. 2017; 55(2):182-196. DOI: 10.1093/chromsci/bmw167. View

Eggers K, Lindahl B . Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins. Curr Cardiol Rep. 2017; 19(4):29. PMC: 5357245. DOI: 10.1007/s11886-017-0840-3. View

Lind L, Sundstrom J, Stenemo M, Hagstrom E, Arnlov J . Discovery of new biomarkers for atrial fibrillation using a custom-made proteomics chip. Heart. 2016; 103(5):377-382. DOI: 10.1136/heartjnl-2016-309764. View

10.

Stenemo M, Nowak C, Byberg L, Sundstrom J, Giedraitis V, Lind L . Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail. 2017; 20(1):55-62. DOI: 10.1002/ejhf.980. View

11.

Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B . Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J. 2009; 30(19):2346-53. DOI: 10.1093/eurheartj/ehp261. View

12.

Carlsson A, Nowak C, Lind L, Ostgren C, Nystrom F, Sundstrom J . Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci. 2019; 125(1):37-43. PMC: 7054929. DOI: 10.1080/03009734.2019.1696430. View

13.

Skau E, Henriksen E, Wagner P, Hedberg P, Siegbahn A, Leppert J . GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction. Eur J Prev Cardiol. 2017; 24(15):1576-1583. DOI: 10.1177/2047487317725017. View

14.

Maisel A, Mueller C, Adams Jr K, Anker S, Aspromonte N, Cleland J . State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10(9):824-39. DOI: 10.1016/j.ejheart.2008.07.014. View

15.

Vavruch C, Nowak C, Feldreich T, Ostgren C, Sundstrom J, Soderberg S . Using proximity extension proteomics assay to discover novel biomarkers associated with circulating leptin levels in patients with type 2 diabetes. Sci Rep. 2020; 10(1):13097. PMC: 7403414. DOI: 10.1038/s41598-020-69473-2. View

16.

Blanche P, Dartigues J, Jacqmin-Gadda H . Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013; 32(30):5381-97. DOI: 10.1002/sim.5958. View

17.

Mohammad M, Koul S, Egerstedt A, Smith J, Noc M, Lang I . Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction. Sci Rep. 2020; 10(1):18663. PMC: 7596042. DOI: 10.1038/s41598-020-75399-6. View

18.

Lind L, Siegbahn A, Lindahl B, Stenemo M, Sundstrom J, Arnlov J . Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip. Stroke. 2015; 46(12):3340-7. DOI: 10.1161/STROKEAHA.115.010829. View

19.

Solier C, Langen H . Antibody-based proteomics and biomarker research - current status and limitations. Proteomics. 2014; 14(6):774-83. DOI: 10.1002/pmic.201300334. View

20.

Nowak C, Carlsson A, Ostgren C, Nystrom F, Alam M, Feldreich T . Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes. Diabetologia. 2018; 61(8):1748-1757. PMC: 6061158. DOI: 10.1007/s00125-018-4641-z. View